Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/30 and B/90) and approved for hospital use (B/30, B/90 and B/100) for the new indication: “Stable coronary artery disease: Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation”.
-
Clinical Benefit
| Substantial |
The actual medical benefit of these medicinal products is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that COVERSYL provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in the management of patients with stable coronary artery disease and a history of myocardial infarction and/or revascularisation with no ventricular dysfunction, as evaluated in the EUROPA study. |
Contact Us
Évaluation des médicaments
